Lyell Immunopharma, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lyell Immunopharma, Inc. is a clinical-stage biotechnology firm dedicated to advancing T-cell therapies for patients battling various cancers. The company focuses on overcoming key challenges in adoptive cell therapy through its innovative technology platforms. These include Gen-R, an ex vivo genetic reprogramming approach designed to enhance T-cell functionality and resistance to exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method aimed at generating robust T cells with durable stemness. Lyell's current pipeline features Ronde-cel (LYL314), a dual-targeting CAR T-cell candidate showing promising results for large B-cell lymphoma and now in a pivotal trial, as well as LYL273, a CAR T-cell therapy targeting metastatic colorectal cancer. The company also maintains a research and development partnership with GlaxoSmithKline to further T-cell receptor (TCR) therapies, including those directed at the NY-ESO-1 antigen. Established in 2018, Lyell Immunopharma, Inc. operates from its headquarters in South San Francisco, California.
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)
Lyell Immunopharma Announces Participation in May Investor Conferences
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Increase in Short Interest
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX)